Alpine Immune Sciences shares are trading higher after Wedbush maintained an Outperform rating on the stock and raised its price target from $26 to $35.
Portfolio Pulse from Benzinga Newsdesk
Alpine Immune Sciences' stock (ALPN) is trading higher following an Outperform rating confirmation and a price target increase from $26 to $35 by Wedbush.
January 26, 2024 | 5:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush has maintained an Outperform rating on Alpine Immune Sciences and increased the price target from $26 to $35, causing the stock to trade higher.
The positive outlook from a reputable analyst firm like Wedbush typically instills confidence in investors, leading to an increase in stock price. The substantial raise in the price target suggests a strong conviction in the company's future performance, which can have a significant positive impact on the stock's short-term trading.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100